Researchers at the Jenner Institute in Oxford and the Ludwig Institute for Cancer Research have designed a two-dose therapeutic vaccine against cancer using the technology used in the COVID vaccine, the scientists said in a study published in the Journal for ImmunoTherapy of Cancer.
The vaccine is set to enter human studies later this year, after studies in mice showed a reduction in tumor size and an improved survival rate.
Vaccine research has advanced following the pandemic, scientists and governments have worked faster than ever and with more resources to try to find vaccines that would help stop the virus. Successful development of COVID vaccines has increased confidence in the approach to other diseases such as cancer.
The cancer vaccine developed by Oxford University uses the vector also used in the COVID vaccine, for one of the doses, to carry the genetic code that helps the body target two proteins present on the surface of many types of cancer cells. Vaccine technology has been shown to generate strong T cell responses, which are needed to fight tumors.
“This new vaccine platform has the potential to revolutionize cancer treatment,” said Adrian Hill, director of the Jenner Institute.
80 patients with lung cancer will participate in the early-stage study.
–
For the most important news of the day, broadcast in real time and presented equidistantly, LIKE our Facebook page!
Follows Mediafax on Instagram to see spectacular images and stories from around the world!
The content of the website www.mediafax.ro is intended exclusively for your personal information and use. It is prohibited republishing the content of this site in the absence of an agreement from MEDIAFAX. To obtain this agreement, please contact us at [email protected].
